Filing Analysis
NeuroOne Medical Technologies Corporation announced the successful completion of three large animal procedures using its StereoCED™ platform. The filing serves as a formal announcement of clinical/pre-clinical progress via a press release.
📋 Key Facts
- Announced the performance of three procedures in large animals using the StereoCED™ platform.
- The announcement was made via a press release dated August 27, 2026.
- The filing includes the press release as Exhibit 99.1.
NeuroOne Medical Technologies Corp has filed an updated Prospectus Supplement to its existing 'at the market' (ATM) offering program. The company intends to sell up to $13.4 million of its common stock through JonesTrading Institutional Services LLC.
🚩 Red Flags
- Potential for significant shareholder dilution given the $13.4 million offering size relative to typical micro-cap market caps.
📋 Key Facts
- The company is utilizing a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC.
- The updated Prospectus Supplement was filed on June 12, 2026.
- The total amount of shares to be offered under this updated supplement is up to $13.4 million.
- The offering is conducted as an 'at the market' (ATM) offering pursuant to Rule 415(a)(4) of the Securities Act of 1933.
NeuroOne Medical Technologies Corporation (NMTC) disclosed on May 21, 2026 that its Audit Committee determined the interim financial statements in its 10-Q for the quarter ended March 31, 2026 (filed May 12, 2026) must be restated due to revenue recognition errors. The errors stemmed from inadequate internal controls over customer-modified purchase orders, resulting in overstated revenue of ~$529K and overstated gross profit of ~$296K. The company intends to file an amended 10-Q as soon as practicable.
🚩 Red Flags
- Revenue recognition restatement signals weak internal controls over order-to-cash processes, particularly for customer-modified purchase orders
- Multiple 8-K items filed simultaneously (4.02 + 7.01), indicating broader disclosure obligations triggered
- Restatement affects both Q3 FY2026 and the six-month YTD period, widening the scope of unreliable financials
- Preliminary estimates subject to further revision — final restatement impact could be larger than disclosed
- Internal control deficiency (inadequate design and implementation) may indicate a material weakness requiring disclosure in forthcoming amended 10-Q
- Small-cap company (~micro-cap NMTC) restatements often face heightened investor scrutiny and potential Nasdaq compliance concerns
- Only ~10 days elapsed between original 10-Q filing (May 12) and non-reliance determination (May 21), suggesting the error was caught quickly but also raises questions about QC processes
📋 Key Facts
- Audit Committee determination date: May 21, 2026
- Affected filing: 10-Q for quarter ended March 31, 2026, originally filed May 12, 2026
- Revenue and accounts receivable overstated by ~$529 thousand for both the three-month and six-month periods ended March 31, 2026
- Gross profit overstated by ~$296 thousand for both the three-month and six-month periods ended March 31, 2026
- Operating loss and net loss understated by ~$296 thousand for both periods
- Total assets overstated by ~$296 thousand as of March 31, 2026
- Inventory understated by ~$233 thousand as of March 31, 2026
- Root cause: inadequate design and implementation of internal controls over customer-modified purchase orders
- No intentional misconduct identified by management or employees
- Independent auditor: Baker Tilly US, LLP has been consulted
- Restatement figures are preliminary and subject to further changes
- Filing also includes Item 7.01 Regulation FD disclosure via press release dated May 22, 2026
- CEO David Rosa signed the 8-K on May 22, 2026
NeuroOne Medical Technologies Corp announced its financial results for the fiscal quarter ended March 31, 2026. The disclosure was made via a press release furnished under Item 2.02 of the 8-K filing.
📋 Key Facts
- The company reported financial results for the fiscal quarter ended March 31, 2026.
- The press release was issued on May 12, 2026.
- The information was furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
NeuroOne Medical Technologies has regained compliance with Nasdaq's $1.00 minimum bid price requirement. The company had been under a deficiency notice since May 6, 2025, and successfully closed the matter by maintaining a bid price above $1.00 for 10 consecutive business days.
🚩 Red Flags
- The company was in non-compliance for nearly a full year (May 2025 to April 2026), indicating a long period of share price underperformance.
📋 Key Facts
- The company received a deficiency letter from Nasdaq on May 6, 2025, regarding the $1.00 minimum bid price rule.
- On April 30, 2026, Nasdaq notified the company that it had regained compliance.
- Compliance was achieved by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days.
- The matter is now considered closed by Nasdaq Listing Qualifications Department.
NeuroOne Medical Technologies announced the retirement of CFO Ronald McClurg, effective June 30, 2026. He will be succeeded by the current COO, Christopher Volker, on July 1, 2026, with McClurg remaining as a Senior Advisor through the end of the year to ensure a smooth transition.
📋 Key Facts
- CFO Ronald McClurg to retire effective June 30, 2026.
- Current COO Christopher Volker will assume the CFO role on July 1, 2026.
- Christopher Volker's base salary will increase to $350,000 upon appointment.
- McClurg will remain as a Senior Advisor until December 31, 2026.
- The successor, Christopher Volker, holds a Wharton MBA and a CFA designation, with prior experience at Abbott and St. Jude Medical.
NeuroOne Medical Technologies Corp has announced a 1-for-6 reverse stock split of its common stock, effective April 15, 2026. The action is primarily intended to increase the per-share bid price to regain compliance with Nasdaq's minimum bid price requirements.
🚩 Red Flags
- Reverse stock split (1-for-6 ratio) typically indicates a struggle to maintain the $1.00 Nasdaq minimum bid price.
- The filing explicitly mentions the need to 'regain compliance with the minimum bid price requirement for continued listing'.
📋 Key Facts
- The reverse stock split ratio is 1-for-6.
- The split becomes effective at 5:00 p.m. Eastern Time on April 15, 2026.
- Trading on a split-adjusted basis will commence on the Nasdaq Capital Market on April 16, 2026.
- No fractional shares will be issued; stockholders entitled to fractional shares will receive a cash payment.
- The number of authorized shares and the par value of the common stock remain unchanged.
- A new CUSIP number (64130M308) has been assigned to the common stock.
NeuroOne Medical Technologies stockholders approved a reverse stock split with a ratio between 1-for-2 and 1-for-15 and authorized an amendment to the 2025 Equity Incentive Plan. The plan amendment increases the share pool by 1.5 million shares and adds a 5% annual evergreen provision through 2031.
🚩 Red Flags
- Approval of a reverse stock split, typically indicative of a need to maintain Nasdaq's minimum bid price requirement.
- Significant potential for shareholder dilution via the 1.5 million share increase and the 5% annual evergreen provision.
📋 Key Facts
- Stockholders approved a reverse stock split at a ratio range of 1-for-2 to 1-for-15, to be determined by the Board.
- The 2025 Equity Incentive Plan was amended to increase the share reserve by 1,500,000 shares.
- An 'evergreen' provision was approved to automatically increase the equity plan shares by 5% of fully diluted shares annually from 2027 to 2031.
- Baker Tilly US, LLP was ratified as the independent auditor for the fiscal year ending September 30, 2026.
- Approximately 59.72% of outstanding shares were represented at the Annual Meeting held on April 3, 2026.
NeuroOne Medical Technologies Corp has scheduled its 2026 Annual Meeting of Stockholders for April 3, 2026. Because this date is more than 30 days from the anniversary of the 2025 meeting, the company has set a new deadline of March 4, 2026, for stockholder proposals.
📋 Key Facts
- The 2026 Annual Meeting of Stockholders is scheduled for April 3, 2026.
- The deadline for receipt of stockholder proposals under Rule 14a-8 is March 4, 2026.
- The meeting date change exceeds 30 calendar days from the anniversary of the 2025 annual meeting.
NeuroOne Medical Technologies Corporation issued an 8-K to announce its financial results for the fiscal quarter ended December 31, 2025. The filing serves as a formal announcement of the press release containing these results.
📋 Key Facts
- The company announced financial results for the fiscal quarter ended December 31, 2025.
- The report was filed on February 17, 2026.
- Financial results were released via a press release (Exhibit 99.1).
NeuroOne Medical Technologies Corp announced the appointment of Jason R. Mills to its Board of Directors as a Class I director, effective December 18, 2025. The board size was increased from four to five members to accommodate this appointment.
📋 Key Facts
- Board size increased from four to five members.
- Jason R. Mills appointed as Class I director, effective Dec 18, 2025.
- Mills will serve on the Compensation and Nominating & Corporate Governance Committees starting Jan 1, 2025.
- Mills currently serves as EVP of Strategy at Penumbra, Inc. (NYSE-listed).
- Mills has a background in med-tech equity research (Canaccord Genuity) and holds degrees from Yale and Ohio University.
NeuroOne Medical Technologies Corporation has filed an 8-K to furnish its financial results for the fiscal quarter and year ended September 30, 2025. The filing serves as a formal announcement of the company's periodic earnings release.
📋 Key Facts
- The filing reports on financial results for the fiscal quarter and year ended September 30, 2025.
- Results were announced via press release dated December 17, 2025.
- The report was signed by CEO David Rosa.
NeuroOne Medical Technologies Corp has received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement. The company must meet this requirement by May 4, 2026, or face potential delisting.
🚩 Red Flags
- Continued non-compliance with Nasdaq minimum bid price requirement ($1.00).
- Risk of delisting from the Nasdaq Capital Market if compliance is not achieved by May 2026.
- History of non-compliance (initial notice was issued on May 9, 2025).
📋 Key Facts
- Nasdaq granted a 180-day extension until May 4, 2026, to cure the minimum bid price deficiency.
- The company is currently non-compliant with Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 minimum bid price requirement.
- The initial compliance period expired on November 3, 2025.
- Failure to regain compliance by May 4, 2026, may result in a delisting determination and subsequent appeal process.
NeuroOne Medical Technologies Corporation issued a press release announcing preliminary, unaudited financial results for the fiscal year ended September 30, 2025. The company reported annual total product revenue of approximately $9.1 million and cash reserves of $6.6 million.
🚩 Red Flags
- Preliminary results are unexamined by independent auditors and subject to material revision.
- Forward-looking statements include risks regarding capital requirements and ability to raise additional funds.
📋 Key Facts
- Preliminary annual total product revenue: ~$9.1 million (FY ended Sept 30, 2025).
- Cash and cash equivalents at September 30, 2025: ~$6.6 million.
- Results are unaudited and subject to change pending final audit procedures.
NeuroOne Medical Technologies Corporation announced it has received FDA 510(k) clearance for its OneRF® Trigeminal Nerve Ablation System. This device is intended for creating radiofrequency lesions to treat pain or for functional neurosurgical procedures.
📋 Key Facts
- FDA 510(k) clearance received on August 18, 2025.
- Product: OneRF® Trigeminal Nerve Ablation System.
- Indication: Use in procedures to create radiofrequency lesions for pain treatment or functional neurosurgical procedures.
NeuroOne Medical Technologies Corp has filed an updated Prospectus Supplement to increase the capacity of its 'at-the-market' (ATM) equity offering program. The company intends to sell up to $6.75 million in common stock through JonesTrading Institutional Services LLC.
🚩 Red Flags
- Potential dilution for existing shareholders due to the ATM equity program.
- Increased supply of common stock can create downward pressure on the share price during the offering period.
📋 Key Facts
- Updated Prospectus Supplement filed on August 15, 2025.
- The offering is part of an existing Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC (dated Dec 21, 2022).
- Total amount to be offered/sold under the updated supplement: up to $6.75 million.
- Method of sale: 'At-the-market' (ATM) offering via Rule 415(a)(4).
- Legal opinion from Honigman LLP was provided regarding the shares.
NeuroOne Medical Technologies Corporation filed an 8-K to furnish its quarterly earnings press release for the fiscal quarter ended June 30, 2025.
📋 Key Facts
- The filing is a standard announcement of financial results for the period ending June 30, 2025.
- The company issued a press release (Exhibit 99.1) containing the earnings data.
- Report date: August 14, 2025.
NeuroOne Medical Technologies Corporation issued an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025. The filing also includes an updated corporate presentation.
📋 Key Facts
- Reported date of event: May 13, 2025
- Fiscal quarter end date: March 31, 2025
- The company released its quarterly financial results via press release (Exhibit 99.1)
- An updated corporate presentation was posted to the investor website (Exhibit 99.2)
NeuroOne Medical Technologies Corp received a notice from Nasdaq stating it is in non-compliance with the minimum bid price requirement because its stock closed below $1.00 for 30 consecutive business days. The company has until November 3, 2025, to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5550(a)(2))
- Sustained low stock price (<$1.00) indicating potential loss of investor confidence or fundamental weakness
- Risk of delisting if compliance is not achieved by November 3, 2025
📋 Key Facts
- Received Nasdaq notice on May 6, 2025.
- Non-compliance due to closing bid price being below $1.00 for the prior 30 consecutive business days.
- Compliance period of 180 calendar days expires on November 3, 2025.
- To regain compliance, stock must close at or above $1.00 for a minimum of 10 consecutive business days.
- Company may be eligible for an additional 180-day extension if it meets market value requirements and provides notice of intent to cure.
NeuroOne Medical Technologies Corporation entered into an underwriting agreement to issue 16,000,000 shares of common stock at $0.50 per share. The offering closed on April 7, 2025, with proceeds intended for general working capital.
🚩 Red Flags
- Significant dilution: The issuance of 16M shares represents a massive increase in the share count relative to the post-offering total (approx. 48% increase).
- Low share price: Offering price of $0.50 per share suggests potential liquidity/capital constraints.
- Use of proceeds for 'general working capital' often indicates immediate cash runway needs.
📋 Key Facts
- Issuance of 16,000,000 shares of common stock at $0.50 per share.
- Underwriter: Ladenburg Thalmann & Co. Inc.
- Over-allotment option: Up to 2,400,000 additional shares exercisable for 45 days.
- Offering closed on April 7, 2025.
- Post-offering shares outstanding: 49,797,000 shares.
- Lock-up period: 75 days following the closing of the offering for executive officers and directors.
NeuroOne Medical Technologies Corporation (NMTC) filed an 8-K/A to report the results of its annual meeting held on February 14, 2025. Most notably, stockholders approved a proposal for a reverse stock split in a ratio between 1-for-2 and 1-for-15.
🚩 Red Flags
- Approval of a reverse stock split (ratio up to 1-for-15) is often used to regain compliance with exchange listing requirements or to boost share price due to low trading value.
📋 Key Facts
- Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split (ratio 1-for-2 to 1-for-15) at the Board's discretion.
- The 2025 Equity Incentive Plan was approved, allowing for the issuance of up to 3,000,000 shares of common stock plus any forfeited shares from the 2017 plan.
- David Rosa was elected as a Class II director (serving until 2028).
- Baker Tilly U.S., LLP was ratified as the independent registered public accounting firm for fiscal year ending Sept 30, 2025.
- The annual meeting saw approximately 58.7% of outstanding common stock represented in voting (18,117,638 shares).
NeuroOne Medical Technologies Corporation held its annual meeting on February 14, 2025, where stockholders approved a reverse stock split in a range of 1-for-2 to 1-for-15. The meeting also resulted in the election of a Class II director and ratification of Baker Tilly U.S., LLP as auditors.
🚩 Red Flags
- Approval of a reverse stock split is often used to address Nasdaq minimum bid price requirements or to improve share price perception.
- The wide range of the potential split (up to 1-for-15) indicates significant volatility/uncertainty regarding the required consolidation ratio.
📋 Key Facts
- Stockholders approved an amendment to the Certificate of Incorporation for a reverse stock split (ratio between 1-for-2 and 1-for-15) to be determined by the Board.
- David Rosa was elected to the Class II director position with 11,724,206 votes in favor.
- Baker Tilly U.S., LLP was ratified as the independent registered public accounting firm for fiscal year ending Sept 30, 2025.
- The 2025 Equity Incentive Plan was approved by stockholders.
- Quorum was met with 18,117,638 shares present (approx. 58.7% of outstanding shares).
NeuroOne Medical Technologies Corporation issued an 8-K to announce the release of its financial results for the fiscal quarter ended December 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Financial results pertain to the fiscal quarter ended December 31, 2024.
- The company issued a press release on February 12, 2025, as Exhibit 99.1.
NeuroOne Medical Technologies Corporation has successfully regained compliance with Nasdaq's minimum bid price requirement. Consequently, the company's scheduled hearing before the Nasdaq Hearings Panel has been cancelled, and its common stock will remain listed on the Nasdaq Stock Market.
🚩 Red Flags
- Historical delisting risk (the company was previously facing potential removal due to low share price).
📋 Key Facts
- The Company received a letter from Nasdaq confirming compliance with Listing Rule 5550(a)(2) regarding minimum bid price requirements.
- The hearing before the Nasdaq Hearings Panel has been cancelled as a result of regaining compliance.
- Common stock (Ticker: NMTC) will remain listed on the Nasdaq Stock Market LLC.
NeuroOne Medical Technologies Corporation filed an 8-K to furnish a Letter to Shareholders authored by CEO Dave Rosa. The letter discusses company achievements, progress, and strategic direction.
📋 Key Facts
- The filing was made pursuant to Item 7.01 (Regulation FD Disclosure).
- CEO Dave Rosa issued a Letter to Shareholders dated January 14, 2025.
- The letter covers company achievements, ongoing progress, and value creation strategy.
NeuroOne Medical Technologies Corporation received a notice from Nasdaq confirming continued non-compliance with the Minimum Bid Price Requirement. The company's stock is facing delisting from the Nasdaq Capital Market unless it successfully appeals via a hearing before the Nasdaq Hearings Panel.
🚩 Red Flags
- Delisting notice from Nasdaq due to stock price falling below $1.00 for 30 consecutive trading days.
- Failure to meet the compliance deadline originally set in July 2024.
📋 Key Facts
- The company failed to regain compliance with the $1.00 minimum bid price requirement by the January 7, 2025 deadline.
- Nasdaq issued a letter on January 8, 2025, indicating continued non-compliance.
- The company intends to request a hearing before the Nasdaq Hearings Panel to appeal the delisting determination.
- A request for a hearing will stay further delisting actions pending the outcome of the panel process.
NeuroOne Medical Technologies Corporation issued a press release announcing preliminary, unaudited revenue results for the first fiscal quarter of 2025 ended December 31, 2024. The company also updated its corporate presentation on its website.
🚩 Red Flags
- Preliminary results are unaudited and may differ from final audited figures.
📋 Key Facts
- Announced preliminary financial results for Q1 2025 (ended Dec 31, 2024).
- Results are unaudited and subject to change pending year-end closing and auditing procedures.
- Updated corporate presentation was posted to the company's investor relations website.
NeuroOne Medical Technologies issued an 8-K to provide a liquidity update regarding its stockholders' equity position. The company notes that while its 10-K reported equity below $2.5 million, subsequent cash inflows have restored the balance above that threshold.
🚩 Red Flags
- Historical low stockholders' equity (below $2.5M) as of Sept 30, 2024, indicating significant liquidity/solvency pressure during that period.
- Reliance on a single large payment ($3.0M from Zimmer) to rectify the equity position.
📋 Key Facts
- Company released Q3 and FY 2024 financial results on December 17, 2024 (Item 2.02).
- As of September 30, 2024, stockholders' equity was reported below $2.5 million in the 10-K.
- The company received a $3.0 million payment related to an Amended and Restated Distribution Agreement with Zimmer dated October 25, 2024.
- Management believes current stockholders' equity is now at least $2.5 million due to the Zimmer payment and subsequent product revenue.
NeuroOne Medical Technologies Corporation has mutually terminated a Loan and Security Agreement with Growth Opportunity Funding, LLC. As of the termination date on November 7, 2024, the company reported no outstanding loan balance.
📋 Key Facts
- Termination Date: November 7, 2024
- Counterparty: Growth Opportunity Funding, LLC
- Agreement being terminated: Loan and Security Agreement dated August 2, 2024
- Outstanding Balance: $0.00 (no loan balance outstanding as of termination)
NeuroOne Medical Technologies entered into an amended and restated exclusive distribution agreement with Zimmer, Inc. for the OneRF Ablation System. The deal includes a $3.0 million upfront payment and potential milestone payments.
🚩 Red Flags
- Zimmer maintains a broad termination right (termination for convenience) with only 90 days' notice, which creates significant counterparty risk and uncertainty regarding long-term revenue stability.
📋 Key Facts
- Effective Date of Agreement: October 25, 2024
- Upfront Payment: $3.0 million due within 10 business days of the effective date
- Milestone Payments: Up to an additional $1.0 million based on net sales targets
- Agreement Term: Expires September 30, 2034, unless terminated earlier
- Termination Rights: Zimmer may terminate for any reason with 90 days' notice; NeuroOne has protection if Zimmer acquires competitors
NeuroOne Medical Technologies Corporation has amended employment agreements for its top four executive officers to revise severance benefits specifically triggered by a change in control. These amendments focus on increasing payouts and accelerating equity vesting if the company is acquired or undergoes a leadership change due to a merger.
🚩 Red Flags
- Increased cash/equity liabilities in the event of an acquisition (potential friction for buyers).
📋 Key Facts
- Amendments made to employment agreements/offer letters for CEO David Rosa, CFO Ronald McClurg, COO Christopher Volker, and CTO Steve Mertens.
- CEO David Rosa's severance: 2.0x base salary + 2.0x target bonus, full equity vesting, and 24 months of company-paid health insurance if terminated without cause or for good reason near a change in control.
- Other Executives (CFO, COO, CTO) severance: 1.25x base salary + 1.25x target bonus, full equity vesting, and 15 months of company-paid health insurance under similar conditions.
- The changes are specifically tied to a 'change in control' event occurring within 12 months after or 3 months prior to the effective date.
NeuroOne Medical Technologies Corporation issued an 8-K to announce its financial results for the fiscal quarter ended June 30, 2024. The filing serves as a formal announcement of the earnings release via press release.
📋 Key Facts
- The company announced financial results for the fiscal quarter ended June 30, 2024.
- The announcement was made on August 14, 2024.
- Financial results were released via a press release (Exhibit 99.1).
NeuroOne Medical Technologies completed a $2.65 million private placement of common stock and warrants, alongside entering into a $3.0 million delayed draw term loan facility secured by substantially all company assets.
🚩 Red Flags
- Multiple 8-K items detected (Material Agreement, Direct Financial Obligation, Unregistered Sales).
- High-interest debt (10% per annum) secured by substantially all company assets.
- Potential dilution via significant warrant issuances to both equity investors and the lender.
- Related-party transaction involving a Board Director in the private placement.
📋 Key Facts
- Private Placement: Issued 2,944,446 shares and 2,208,333 PIPE Warrants at $0.90 per unit; total gross proceeds ~$2.65 million.
- PIPE Warrants: Exercise price of $1.19 per share; expires in three years.
- Debt Facility: $3.0 million delayed draw term loan from Growth Opportunity Funding, LLC with 10% annual interest.
- Security Interest: Debt is secured by a first-priority security interest in substantially all company assets.
- Lender Warrants: Issued warrants to the lender for 100,000 shares at $0.66/share (closing date) plus additional warrants upon borrowing.
- Related Party: One purchaser in the private placement is Paul Buckman, a director on the Company's Board of Directors.
NeuroOne Medical Technologies Corporation received a notice from Nasdaq stating it is non-compliant with the minimum bid price requirement because its stock closed below $1.00 for 30 consecutive business days.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5550(a)(2))
- Stock price has been below the $1.00 threshold for 30 consecutive business days, indicating significant downward momentum or lack of market interest.
📋 Key Facts
- Received Nasdaq Notice on July 11, 2024.
- Non-compliance due to closing bid price being below $1.00 per share for the prior 30 consecutive business days.
- The Company has a 180-day compliance period ending January 7, 2025, to regain compliance.
- To regain compliance, the stock must close at or above $1.00 per share for at least 10 consecutive business days.
NeuroOne Medical Technologies Corporation has adopted Amended and Restated Bylaws effective June 20, 2024. The changes primarily focus on quorum requirements, universal proxy rules compliance, and stockholder nomination procedures.
🚩 Red Flags
- Reduction of quorum requirement from a majority to one-third can make it easier for small groups of shareholders to pass resolutions, which is sometimes viewed as a defensive measure or a shift in corporate governance control.
📋 Key Facts
- Board approved Amended and Restated Bylaws on June 20, 2024.
- Quorum requirement for stockholder meetings reduced from a majority to one-third of voting power.
- Bylaws updated to comply with SEC universal proxy rules regarding director nominations.
- New requirements for stockholders/groups calling special meetings to nominate directors (must hold 10% of votes).
- Enhanced disclosure requirements for stockholder nominations and proposals.
NeuroOne Medical Technologies Corporation filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2024. The filing serves as a formal mechanism to furnish the quarterly press release via Exhibit 99.1.
📋 Key Facts
- Report date: May 14, 2024
- Fiscal period covered: Quarter ended March 31, 2024
- The filing includes a press release regarding financial results as Exhibit 99.1
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
NeuroOne Medical Technologies Corporation announced the upcoming limited commercial launch and shipping of its OneRF™ Ablation System, scheduled to begin the week of March 26, 2024.
📋 Key Facts
- Company expects to start shipping systems of its OneRF™ Ablation System during the week of March 25, 2024.
- The shipment is part of a limited commercial launch for the product.
- Announcement made via press release on March 26, 2024.
NeuroOne Medical Technologies Corporation reported the results of its annual meeting of stockholders held on March 14, 2024. The company successfully elected a director, ratified its independent auditor, and approved executive compensation advisory votes.
📋 Key Facts
- Annual Meeting held on March 14, 2024, with 15,782,424 shares present (approx. 60.89% of outstanding shares).
- Paul Buckman was elected to the Class I director seat for a three-year term ending at the 2027 annual meeting.
- Baker Tilly U.S., LLP was ratified as the independent registered public accounting firm for fiscal year ending Sept 30, 2024.
- Stockholders approved an advisory vote to conduct executive compensation votes every three years.
- The company updated its corporate presentation on March 15, 2024.
NeuroOne Medical Technologies Corporation issued an 8-K to announce its financial results for the fiscal quarter ended December 31, 2023. The filing serves as a formal notice that a press release containing these results was issued on February 13, 2024.
📋 Key Facts
- Company announced financial results for the fiscal quarter ended December 31, 2023.
- The announcement was made via a press release dated February 13, 2024.
- Results are furnished as Exhibit 99.1 and are not considered 'filed' under Section 18 of the Exchange Act.